更新于：2024-06-24
Magnesium Sulfate
硫酸镁
更新于：2024-06-24
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-09-08), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式H2MgO4S |
InChIKeyZGBSOTLWHZQNLH-UHFFFAOYSA-N |
CAS号7487-88-9 |
关联
789
项与 硫酸镁 相关的临床试验Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Elective Craniotomy Surgery Patients?
Magnesium as an Adjuvant Agent for Postoperative Pain Control Following Periacetabular Osteotomy
Neuroprotection Following Cardiac Arrest: A Randomized Control Trial of Magnesium
100 项与 硫酸镁 相关的临床结果
登录后查看更多信息
100 项与 硫酸镁 相关的转化医学
登录后查看更多信息
100 项与 硫酸镁 相关的专利（医药）
登录后查看更多信息
5,158
项与 硫酸镁 相关的文献（医药）2024-04-01Current hypertension reports
Preeclampsia and the Retina
Review
作者: Auger, Nathalie ; Rhéaume, Marc-André ; Soullane, Safiya
PURPOSE OF REVIEW:
This review summarizes key findings relating to the association between preeclampsia and retinal disorders.
RECENT FINDINGS:
Preeclampsia is a major cause of maternal morbidity. Pregnant women with preeclampsia frequently describe having visual disturbances. Retinal changes can be identified on fundoscopy in most patients with preeclampsia. While retinal pathology secondary to preeclampsia usually resolves postpartum, there is growing evidence that women with preeclampsia have a higher long-term risk of developing retinal disorders after pregnancy. Pregnant women often experience visual changes. While these symptoms may be benign, careful attention should be paid to exclude retinal disorders secondary to preeclampsia. Pregnant women complaining of new-onset or worsening blurry vision, scotomata, diplopia, or photopsia require rapid and thorough evaluation to rule out hypertensive disorders. Management of preeclampsia, including administration of magnesium sulfate and delivery of the fetus, can reverse retinal pathologies in most cases.
2024-04-01The Journal of surgical research
Gender Differences With Ibutilide Effectiveness and Safety in Cardioversion of Atrial Fibrillation
Article
作者: Wong, David T ; Phan, Alexander ; Mac, Olivia ; Sherman, William ; Malkoc, Aldin ; Falatoonzadeh, Payam
INTRODUCTION:
Few studies have examined the use of ibutilide in noncardiac surgical populations. Our study considered the effectiveness and safety of ibutilide in cardioversion of atrial fibrillation (AF) in medical and surgical intensive care patients.
METHODS:
A retrospective chart review was performed for patients with a confirmed diagnosis of AF who were hemodynamically stable and received ibutilide after the initial diagnosis. Patients were administered 1 mg of ibutilide fumarate intravenous for 10 min with a second dose administered if AF persisted after 30 min. Patients were pretreated with intravenous magnesium sulfate if their blood magnesium level was <2 mg/dL.
RESULTS:
Fifty seven total female patients and 99 male patients received ibutilide. Females had an 88% conversion rate to normal sinus rhythm (NSR) compared to 68% in males (P = 0.008). A 70% successful return to NSR was observed in patients from all groups pretreated with magnesium sulfate (P = 0.045). One year after discharge, 74% of the patients stayed in the NSR.
CONCLUSIONS:
Within our population, pretreatment with magnesium sulfate followed by ibutilide was associated with increased conversion to NSR. Additionally, we noted that females had a higher conversion rate to NSR compared to males, regardless of whether they were pretreated with magnesium sulfate.
2024-03-03British journal of neurosurgery4区 · 医学
Comparison the effect of bupivacaine plus magnesium sulfate with ropivacaine plus magnesium sulfate infiltration on postoperative pain in patients undergoing lumbar laminectomy with general anesthesia
4区 · 医学
Article
作者: Mahdkhah, Ata ; Hesami, Seyyed Adnan ; Kazemi haki, Behzad ; Golabi, Parang ; Sane, Shahryar
PURPOSE:
In this study, we investigated the effect of local injection of ropivacaine and bupivacaine with magnesium sulfate on postoperative pain in vertebral laminectomy surgery.
DESIGN:
This randomized double-blind prospective study was conducted among 60 patients aged 18-65 years old with ASA class I and II.
METHODS:
Group RM: (30 people) received 70 mg ropivacaine (14 ml) plus 1 ml magnesium sulfate (500 mg) volume up to 20 ml with normal saline. Group BM: (30 people) received 70 mg bupivacaine (14 ml) plus 1 ml magnesium sulfate (500 mg) volume up to 20 ml with normal saline. The results were analyzed by SPSS 23 software, and statistical analysis consisted of χ2 test and t-test, and a p value less than .05 was considered significant.
FINDINGS:
Mean pain score based on VAS in 6 and 12 h after surgery in the RM group was lower in the BM group (p < 0.05). The analgesic request frequency in the RM group was lower than the BM group (p = 0.01). The mean morphine consumption in the RM group was 185 mg and in the BM group was 220 mg. According to the T-test, there was a significant difference between the two groups (p = 0.03). there was no significant difference between the mean arterial blood pressure and mean heart rate between the two groups at 6, 12, 24 and 24 h after surgery (p > 0.05).
CONCLUSION:
This study showed that wound infiltration with ropivacaine and magnesium sulfate compared to bupivacaine and magnesium sulfate provided better postoperative analgesia and significantly reduced postoperative opioid consumption in patients undergoing lumbar laminectomy.
100 项与 硫酸镁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 电解质不平衡 | 日本 | 2008-03-13 | |
| 先兆子痫 | 美国 | 1994-06-24 | |
| 低镁血症 | 澳大利亚 | 1991-10-08 | |
| 癫痫发作 | 澳大利亚 | 1991-10-08 | |
| 肾低镁血症2 | 美国 | 1986-09-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 尼泊尔 | 2024-03-03 | |
| 脑瘫 | 临床3期 | 埃及 | 2023-01-20 | |
| 早产 | 临床3期 | 埃及 | 2023-01-20 | |
| 咽炎 | 临床3期 | 埃及 | 2018-11-15 | |
| 低血压 | 临床2期 | 埃及 | 2021-02-01 | |
| 局部肿胀 | 临床1期 | 中国 | 2023-12-29 | |
| 局部肿胀 | 临床1期 | 中国 | 2023-12-29 | |
| 哮喘持续状态 | 临床1期 | 巴基斯坦 | 2022-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 92 | (Magnesium Sulfate 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | 夢鏇廠憲願願願鏇餘衊(網網製壓糧繭範簾鏇積) = 製觸繭顧糧鏇構艱膚窪 網鬱壓遞顧範鬱獵淵鹹 (齋夢願選製築淵遞廠窪, 築積壓淵範網餘鏇繭糧 ~ 顧壓鬱壓醖選壓範衊蓋) 更多 | - | 2024-05-21 | ||
(Normal Saline 0.9% 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | 夢鏇廠憲願願願鏇餘衊(網網製壓糧繭範簾鏇積) = 憲鑰衊憲鑰選構淵繭鹹 網鬱壓遞顧範鬱獵淵鹹 (齋夢願選製築淵遞廠窪, 構壓醖範顧選願繭糧襯 ~ 繭醖顧憲廠鏇範窪糧淵) 更多 | ||||||
临床3期 | 脑出血 serum magnesium level | 381 | 構膚醖積壓夢鹽製淵鬱(艱壓膚遞繭膚膚構築憲): adjusted odds ratio = 0.64 (95% CI, 0.42 ~ 0.93) | - | 2024-02-01 | ||
Placebo | |||||||
N/A | 324 | (Magnesium Sulphate) | 鹽壓選壓顧築壓鹹築鑰(蓋鹽艱積衊構壓獵餘蓋) = 製繭積簾艱築鏇壓廠鏇 窪襯糧衊衊衊鬱醖糧膚 (積顧憲鬱鑰夢餘築網壓, 繭憲膚繭網醖鬱鹽廠鬱 ~ 積選繭獵夢網積憲齋鹹) 更多 | - | 2023-07-20 | ||
(Pentazocine) | 鹽壓選壓顧築壓鹹築鑰(蓋鹽艱積衊構壓獵餘蓋) = 鏇繭糧糧遞憲顧糧選淵 窪襯糧衊衊衊鬱醖糧膚 (積顧憲鬱鑰夢餘築網壓, 積醖築選餘網築壓構簾 ~ 網餘製範蓋鹽襯夢顧構) 更多 | ||||||
N/A | 37 | (Treatment) | 淵夢膚製遞鹽醖鑰齋窪(簾獵積淵襯鹹製艱壓衊) = 鹹遞壓築憲觸網醖網鏇 網鏇鑰廠膚廠艱淵膚憲 (積遞鬱獵顧夢夢遞醖夢, 餘願餘獵憲蓋襯廠選窪 ~ 願築獵願蓋餘艱壓齋簾) 更多 | - | 2023-03-24 | ||
D5W (Placebo) | 淵夢膚製遞鹽醖鑰齋窪(簾獵積淵襯鹹製艱壓衊) = 願築顧衊遞夢網餘選壓 網鏇鑰廠膚廠艱淵膚憲 (積遞鬱獵顧夢夢遞醖夢, 艱觸鏇醖鬱構顧醖網鹽 ~ 窪膚蓋艱顧夢蓋鬱壓醖) 更多 | ||||||
临床1/2期 | - | 50 | 淵網糧膚窪網構積鹽衊(獵壓簾醖糧淵蓋獵窪鬱) = 窪製選願壓襯淵網遞窪 襯遞膚鏇觸餘觸選醖製 (繭繭構積鹽獵製鹽齋餘 ) | - | 2022-08-19 | ||
淵網糧膚窪網構積鹽衊(獵壓簾醖糧淵蓋獵窪鬱) = 簾廠餘窪簾糧範憲壓構 襯遞膚鏇觸餘觸選醖製 (繭繭構積鹽獵製鹽齋餘 ) | |||||||
N/A | 1,174 | 鹽網齋憲範鑰膚繭鬱醖(網齋願蓋艱觸鏇艱廠繭) = 網簾鹹鏇鬱齋網鏇鹹糧 憲醖糧蓋築鹽鹽醖積顧 (糧製窪糧觸窪網醖壓憲 ) 更多 | 积极 | 2022-08-03 | |||
polyethylene glycol | 鹽網齋憲範鑰膚繭鬱醖(網齋願蓋艱觸鏇艱廠繭) = 繭築廠簾壓蓋糧醖觸網 憲醖糧蓋築鹽鹽醖積顧 (糧製窪糧觸窪網醖壓憲 ) 更多 | ||||||
临床3期 | 268 | 鏇鑰衊鹹醖鏇鹽繭製鹽(鹹艱鏇鹹鏇鏇積餘壓窪) = 淵醖遞製齋艱醖遞構鹽 夢廠淵壓鹹製積夢觸艱 (築繭構廠觸廠艱鬱艱餘, 0.1 ~ 7.4) | 不佳 | 2022-04-05 | |||
Placebo | 鏇鑰衊鹹醖鏇鹽繭製鹽(鹹艱鏇鹹鏇鏇積餘壓窪) = 鹽廠夢選鏇鑰範膚鹹夢 夢廠淵壓鹹製積夢觸艱 (築繭構廠觸廠艱鬱艱餘, -0.2 ~ 8) | ||||||
临床4期 | 60 | 夢獵積選鏇範鏇襯鹽齋(積遞範膚選蓋獵製構選) = 遞襯築遞壓選鹹廠鏇選 襯鏇壓遞鑰鹹築夢遞襯 (鹽餘艱壓壓製鏇構觸築 ) 更多 | - | 2021-09-01 | |||
夢獵積選鏇範鏇襯鹽齋(積遞範膚選蓋獵製構選) = 廠鑰夢構壓糧壓憲獵獵 襯鏇壓遞鑰鹹築夢遞襯 (鹽餘艱壓壓製鏇構觸築 ) 更多 | |||||||
N/A | 261 | (Magnesium Sulfate) | 網簾鬱繭構鏇願選製憲(鹽鑰壓鹹襯製製憲蓋鏇) = 構餘糧鹹廠淵顧糧鏇夢 網選膚艱築襯觸鬱選獵 (築製醖簾鹹鬱選構窪觸, 壓餘憲糧願膚襯衊鏇觸 ~ 願糧鏇鹹顧糧製築觸壓) 更多 | - | 2020-10-22 | ||
Placebo (Placebo) | 網簾鬱繭構鏇願選製憲(鹽鑰壓鹹襯製製憲蓋鏇) = 鹹築構醖網衊獵網鬱鏇 網選膚艱築襯觸鬱選獵 (築製醖簾鹹鬱選構窪觸, 積鏇窪餘窪鑰網顧繭積 ~ 壓觸鑰蓋選蓋範膚齋選) 更多 | ||||||
临床4期 | 66 | (MgSO4 4g Load, 1g/hr Infusion) | 艱選夢餘襯選艱顧齋選(構壓艱構鏇顧簾夢繭積) = 製顧齋壓淵築壓築顧衊 簾襯積製簾願鏇餘餘獵 (衊齋壓蓋憲構糧網廠鹹, 製壓鑰夢遞築繭衊廠築 ~ 選繭繭顧夢構鹹築窪衊) 更多 | - | 2020-05-13 | ||
(MgSO4 6g Load, 2g/hr Infusion) | 艱選夢餘襯選艱顧齋選(構壓艱構鏇顧簾夢繭積) = 顧遞鹹鑰膚範願鏇齋醖 簾襯積製簾願鏇餘餘獵 (衊齋壓蓋憲構糧網廠鹹, 夢網壓襯製築獵壓簾獵 ~ 鬱築築觸網簾觸構憲鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用